LIGHTNING RELEASES: San Diego, California (1/22/2014) – Medical biotechnology company Biostratus Corporation has today announced the issuance of the USPTO Patent #8,586,089 “Enhanced Carriers for the Delivery of Microparticles to Mammalian Tissues and Fluids”.
The Biostratus patent and patents pending cover a novel class of biocompatible injectable materials for the permanent and controllable bulking of human tissues. The improved carrier formulation has been developed to safely and effectively deliver microspheres made of Polymethylmethacrylate (PMMA) or various other biocompatible polymers, to many different types of tissues and fluids. The specially manufactured and controlled microspheres form a scaffold for new host tissue growth after injection, and over time the resultant host tissue reaction naturally replaces the biocompatible carrier material. This particular permanent tissue bulking technology has a wide variety of potential therapeutic applications. More than three dozen indications are covered in the recently issued patent and a follow up Continuation-in-Part application. Potential applicable indications include Gastroenterology, Urology, Periodontal Dentistry, Cardiothoracic and Cardiovascular Surgery, Orthopedic and Spinal Orthopedic Surgery, Plastic and Reconstructive Surgery, Dermatology, Gynecology, Laryngeal & Soft Palate Reconstructive Surgery, Otolaryngology, Bariatric Surgery, Neurology, Ophthalmology, Oncology, and several other listed indications with the potential to offer an effective permanent cure to the various conditions.
“Having developed the ability to tightly control the critical characteristics of our enhanced carrier materials, and by modifying those characteristics and adding different functional supplements and excipients we are now able to offer novel permanent injectable fillers with the ability to treat many different therapeutic indications” said Biostratus Corporations CEO, Russell Anderson. “We believe that this exciting new tissue bulking and treatment technology will provide effective permanent treatment options for many serious medical conditions, including several for which there is no currently effective cure”.
The primary enhanced carrier components and the microspheres have well established safety and biocompatibility profiles, and Biostratus Corporation is currently seeking potential partners and conducting negotiations to license the technology for various indications.
For further information contact: